Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes

We conducted a surveillance epidemiology and end results ( SEER )‐based analysis to describe the incidence and characteristics of second primary acute lymphoblastic leukemia ( sALL ) among adults (≥18 years) with a history of primary malignancies (1M). Standardized incidence ratios ( SIR s) of sALL cases were calculated by site and 1M stage. We also evaluated the differences in 5‐year sALL survival by age, site, and extent of 1M, latency of sALL after 1M, and evidence of underlying racial/ethnic disparity. We identified 10,956 patients with de‐novo/primary acute lymphoblastic leukemia (1 ALL ) and 772 with sALL . Women (49.1% vs. 42.9%), white patients (72.0% vs. 59.5%), older patients (58.8% vs. 25.2%; age ≥65 years), and patients diagnosed between 2003 and 2012 (66.8% vs. 53.9%) had a higher proportion of sALL compared with 1 ALL . There was a significantly inferior median 5‐year survival for sALL patients compared to 1 ALL (6 vs. 15 months; HR 1.20, 95% CI 1.10–1.31, P  < 0.001). The median latency period was 60.0 months; the most common 1M among sALL patients were breast (17.9%) and prostate (17.4%). Patients with any 1M were at increased risk of developing sALL ( SIR 1.76, 95% CI 1.58–1.95, P  < 0.001). Hematological‐1M sites had significantly higher SIR s (hematological‐ SIR 7.35; solid‐ SIR 1.33; P  < 0.001). We observed a significant increase in sALL incidence after a 1M and a significantly worse 5‐year survival with different demographic characteristics from 1 ALL . There is a need to define appropriate screening methods for patients surviving their primary cancer.